Originally published by our sister publication Infectious Disease Special Edition
By Marie Rosenthal, MS
Oral bridging (OB) of lenacapavir enabled patients to maintain viral suppression of their HIV after missing doses of subcutaneous lenacapavir (LEN; Sunlenca, Gilead), according to data presented at IAS 2023, the 12th Annual IAS Conference on HIV Science, held in Brisbane, Australia, and virtually.
In December 2021, the FDA imposed a full clinical hold of subcutaneous LEN because of glass